[en] Stimulation of the dopamine (DA) D-2 and D-1 receptors results in behavioural activation (i.e., induction of contralateral rotations) in 6-hydroxydopamine (6-OHDA) substantia nigra lesioned rats. Competitive N-methyl-D-aspartate (NMDA) antagonists as well as alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) antagonists potentiate the stimulatory responses to threshold doses of L-DOPA or the mixed dopamine D-1/D-2 agonist apomorphine in this model, indicating the potential of such combinations for the management of Parkinson's disease. Neuroanatomic and electrophysiologic data indicate a differential distribution of DA D-1 and DA D-2 receptors within motor loops of the basal ganglia. DA D-1 receptors are preferentially located on GABAergic neurones projecting to the substantia nigra compacta (SNc) and to the substantia nigra reticulata (SNr), whereas DA D-2 receptors are preferentially located on neurones that innervate the external pallidum. NMDA receptors are present in high densities within the striatum, whereas AMPA receptors are enriched in the entopeduncular nucleus/internal pallidum and the SNr. To further characterise the functional interaction between DA and glutamate receptors, we tested the competitive NMDA antagonist 3-((+/-)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP) and the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f] quinoxaline (NBQX) following systemic administration in combination with the DA D-2 selective agonist quinpirole or the DAD-1 selective agonist A 68 930 (1R,3S)-1-aminomethyl-5,6-dihydroxy-3-phenylisochroman) in rats with chronic 6-OHDA lesions of the SNc. CPP potentiated quinpirole-induced rotations and did not affect those induced by the D-1 agonist A 68930. By contrast, NBQX had no effect on quinpirole-induced rotations, whereas synergism was seen with A 68930. These results suggest that rotations induced by combined treatment with glutamate antagonists and DA agonists are mediated by different pathways within the basal ganglia, depending on which subtype of receptor is involved. AMPA antagonists could act preferentially by activating the direct motor pathway, whereas NMDA antagonists could modulate the indirect loop.
Disciplines :
Neurology
Author, co-author :
Löschmann, Peter-Andreas; Department of Neurology, Eberhard-Karls-University Tübingen, Federal Republic of Germany
Wüllner, Ullrich; Department of Neurology, Eberhard-Karls-Univ. Tübingen, Tübingen, Germany
HENEKA, Michael ; Department of Neurology, Eberhard-Karls-Univ. Tübingen, Tübingen, Germany
Schulz, Jörg B.; Department of Neurology, Eberhard-Karls-Univ. Tübingen, Tübingen, Germany
Kunow, Margrit; Research Laboratories of Schering AG, Berlin, Germany
Wachtel, Helmut; Research Laboratories of Schering AG, Berlin, Germany
Klockgether, Thomas; Department of Neurology, Eberhard-Karls-Univ. Tübingen, Tübingen, Germany
External co-authors :
yes
Language :
English
Title :
Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Albin, R.L., Young, A.B., and Penney, J.B. (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci., 12:366-375.
Albin, R.L., Makowiec, R.L., Hollingsworth, Z.R., Dure, L.S., 4th, Penney, J.B., and Young, A.B. (1992) Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience, 46:35-48.
Anderson, J.J., Chase, T.N., and Engber, T.M. (1992) Differential effect of subthalamic nucleus ablation on dopamine D1 and D2 agonist-induced rotation in 6-hydroxydopamine-lesioned rats. Brain Res., 588:307-310.
Baldessarini, R.J., Neumeyer, J.L., Campbell, A., Sperk, G., Ram, V., Arana, G.W., and Kula, N.S. (1982) An orally effective, long-acting dopaminergic prodrug: (-)-10,11-methylendioxy-N-propoylnoraporphine. Eur. J. Pharmacol., 77:87-88.
Bergman, H., Wichmann, T., and DeLong, M.R. (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science, 249:1436-1438.
Bertorello, A.M., Hopfield, J.F., Aperia, A., and Greengard, P. (1990) Inhibition by dopamine of (Na+ + K+)ATPase activity in neostriatal neurons through D1 and D2 dopamine receptor synergism. Nature, 347:386-388.
Braun, A., Fabbrini, G., Mouradian, M.M., Serrati, C., Barone, P., and Chase, T.N. (1987) Selective D-1 dopamine receptor agonist treatment of Parkinson's disease. J. Neural Transm., 68:41-50.
Carlsson, M., and Carlsson, A. (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Transm., 75:221-226.
Carlsson, M., and Carlsson, A. (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia -implications for schizophrenia and Parkinson's disease. Trends Neurosci., 13:272-276.
Carpenter, M.B. (1981) The nervous system II. In: Handbook of Physiology Sect. 1. V.B. Brooks, ed. American Physiological Society, Bethesda, MD, pp. 947-995.
Close, S.P., Marriott, A.S., and Pay, S. (1985) Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. Br. J. Pharmacol., 85:320-322.
Close, S.P., Elliot, P.J., Hayes, A.G., and Marriott. A.S. (1990) Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease. Psychopharmacology, 102:295-300.
Creese, I., Burt, D., and Synder, S.H. (1977) Dopamine receptor binding enhancement accompanies lesion-induced behavioural supersensitivity. Science, 197:596-598.
Crossman, A.R., Peggs, D., Boyce, S., Luquin, M.R., and Sambrook, M.A. (1989) Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology, 28:1271-1273.
Davies, J., Evans, R.H., Herrling, P.L., Jones, A.W., Olverman, H.J., Pook, P., and Watkins, J.C. (1986) CPP, a new potent and selective NMDA antagonist. Depression of central neuron responses, affinity for (3H]D-AP5 binding sites on brain membranes and anticonvulsant activity. Brain Res., 382:169-173.
DeNinno, M.P., Schoenleber, R., MacKenzie, R., Britton, D.R., Asin, K.E., Briggs, C., Trugman, J.M., Ackerman, M., Artman, L., Bednarz, L., Bhatt, R., Curzon, P., Gomez, E., Kang, C.H., Stittsworth, J., and Kebabian, J.W. (1991) A68930: a potent agonist selective for the dopamine D1 receptor. Eur. J. Pharmacol., 199:209-219.
Dragunow, M., Robertson, G.S., Faull, R.L.M., Robertson, H.A., and Jansen, K. (1990) D2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons. Neuroscience, 37:287-294.
Fenu, S., Carta, A., and Morelli, M. (1995) Modulation of dopamine D1-mediated turning behavior and striatal c-fos expression by the substantia nigra. Synapse, 19:233-240.
Foote, R.W., Büscher, H.H., and Römer, D. (1988) CY 208-243: a unique combination of atypical opioid antinociception and D1 dopaminomemetic properties. Life Sci., 42:137-152.
Gerfen, C.R. (1992) The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci., 15:133-139.
Gerfen, C.R., and Young, W.S. (1988) Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res., 460:161-167.
Gerfen, D.K., Engber, T.M., Mahan, L.C., Susel, Z., Chase, T.N., Monsma, K.J., and Sibley, D.R. (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science, 250:1429-1432.
Gerfen, C.R., Keefe, K.A., and Gauda, E.B. (1995) D1 and D2 dopamine receptor function in the striatum: coactivation of D1-and D2-dopamine receptors on separate neurons results in potentiated immediate early gene response in D1-containing neurons. J. Neurosci., 15:8167-8176.
Gossel, M., Schmidt, W.J., Löscher, W., Zajaczkowski, W., and Danysz, W. (1995) Effect of coadministration of glutamate receptor antagonists and dopaminergic agonists on locomotion in monoamine-depleted rats. J. Neural Transm. [P.-D. Sect.], 10:27-39.
Imperato, A., Scrocco, M.G., Bacchi, S., and Angelucci, L. (1990) NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur. J. Pharmacol., 187:555-556.
Jackson, D.M., and Hashizume, M. (1986) Bromocriptine induces marked locomotor stimulation in dopamine depleted mice when D-1 dopamine receptors are stimulated with SKF 38 393. Psychopharmacology, 90:147-149.
Kebabian, J.W., and Calne, D.B. (1979) Multiple receptors for dopamine. Nature, 277:93-96.
Kelland, M.D., Boldry, R.C., Huang, K.X., Chase, T.N., and Walters, J.R. (1991) Dizocilpine (MK 801), but not NBQX, alters dopamine (DA)-mediated changes in striatopallidal neuronal activity and behavior. Soc. Neurosci. Abstr., 17:1349.
Klockgether, T., and Turski, L. (1989) Excitatory amino acids in the basal ganglia: implications for the treatment of Parkinson's disease. Trends Neurosci., 12:285-286.
Klockgether, T., and Turski, L. (1990) NMDA antagonists potentiate antiparkinsonian actions of L-dopamine in monoamine-depleted mice. Ann. Neurol., 28:539-546.
Klockgether, T., and Turski, L. (1993) Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia. Ann. Neurol., 34:585-593.
Klockgether, T., Turski, L., Honoré, T., Zhang, Z., Gash, D.M., Kurlan, R., and Greenamyre, J.T. (1991) The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol., 30:717-723.
Löschmann, P-A., Lange, K.W., Kunow, M., Rettig, K.J., Jähnig, P., Honoré, T., Turski, L., Wachtel, H., Jenner, P., and Marsden, C.D. (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease. J. Neural Transm. [P.-D. Sect.), 3:203-213.
Luquin, M.R., Obeso, J.A., Laguna, J., Guillen, J., and Martinez Lage, J.M.I (1993) The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys. Eur. J. Pharmacol., 235:297-300.
Morelli, M., and Di Chiara, G. (1990) MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease. Eur. J. Pharmacol., 182:611-612.
Morelli, M., Fenu, S., and Di Chiara, G. (1992a) Blockade of N-methyl-D-aspartate receptors potentiates dopaminergic responses in the 6-OHDA model of Parkinson: differential role of D-1 and D-2 receptors. Neurochem. Int., 20 Suppl:261S-264S.
Morelli, M., Fenu, S., Pinna, A., and Di Chiara, G. (1992b) Opposite effects of NMDA receptor blockade on dopaminergic D1-and D2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression. J. Pharmacol. Exp. Ther., 260:402-408.
Nomoto, M., Jenner, P., and Marsden, C.D. (1985) The dopamine D-2 agonist LY 141 865, but not the D-1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Neurosci. Lett., 57:37-41.
Paxinos, G., and Watson, C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
Pifl, C., Reither, H., and Hornykiewicz, O. (1991) Lower efficacy of the dopamine D1 agonist, SKF 38393, to stimulate adenylyl cyclase activity in primate than in rodent striatum. Eur. J. Pharmacol., 202:273-276.
Porter, R.H., Greene, J.G., Higgins, D.S., Jr., and Greenamyre, J.T. (1994) Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion. J. Neurosci., 14:7192-7199.
Price, R.H., Jr., Hollingsworth, Z., Young, A.B., and Penney, J.B., Jr. (1993) Excitatory amino acid receptor regulation after subthalamic nucleus lesions in the rat. Brain Res., 602:157-160.
Robertson, G.S., and Robertson, H.A. (1986) Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats. Brain Res., 384:387-390.
Robertson, G.S., Vincent, S.R., and Fibiger, H.C. (1992) D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience, 49:285-296.
Schmidt, W.J., and Bubser, M. (1989) Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol. Biochem. Behav., 32:621-623.
Setler, P.E., Sarau, H.M., Zirkle, C.L., and Saunders, H.L. (1978) The central effects of a novel dopamine agonist. Eur. J. Pharmacol., 50:419-430.
Sheardown, M.J., Nielsen, E.O., Hansen, A.J., Jacobsen, P., and Honoré, T. (1990) 2,3-Dihydroxy-6-nitro-7-sulfamoylbenz(F)quinoxa-line: a neuroprotectant for cerebral ischemia. Science, 247:571-574.
Sokoloff, P., Giros, B., Martes, M.P., Bouthenet, M.L., and Schwartz, J.C. (1990) Molecular cloning and characterisation of a novel dopamine receptor (D3) as target for neuroleptics. Nature, 347:146-151.
Sonsalla, P.K., Manzino, L., and Heikkila, R.E. (1988) Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway. J. Pharmacol. Exp. Ther., 247:180-185.
Starr, M.S. (1995) Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse, 19:264-293.
Starr, M.S., and Starr, B.S. (1993) Facilitation of dopamine D1 receptor-but not dopamine D1/D2 receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse. Eur. J. Pharmacol., 250:239-246.
Starr, M.S., and Starr, B.S. (1994) Comparison of the effects of NMDA and AMPA antagonists on the locomotor activity induced by selective D1 and D2 dopamine agonists in reserpine-treated mice. Psychopharmacology, 114:469-476.
Stoof, J.C., and Kebabian, J.W. (1981) Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat striatum. Nature, 294:366-368.
Surmeier, D.J., Eberwine, J., Wilson, C.J., Cao, Y., Stefani, A., and Kitai, S.T. (1992) Dopamine receptor subtypes colocalize in rat striatonigral neurons. Proc. Natl. Acad. Sci. U.S.A., 89:10178-10182.
Svensson, A., Carlsson, A., and Carlsson, M.L. (1992) Differential locomotor interactions between dopamine D1/D2 receptor agonists and the NMDA antagonist dizocilpine in mono-amine-depleted mice. J. Neural Transm. [Gen. Sect.], 90:199-217.
Swedberg, M.D.B., Jacobsen, P., and Honoré, T. (1995) Anticonvulsant, anxiolytic and discriminative effects of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX). J. Pharmacol. Exp. Ther., 274:1113-1121.
Temlett, J.A., Quinn, N.P., Jenner, P., Marsden, C.D., Pourcher, E., Bonnet, A.-M., Agid, Y., Markstein, R., and Lataste, X. (1989) Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease. Mov. Disord., 4:261-265.
Ungerstedt, U. (1968) 6-Hydroxydopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol., 5:107-110.
Wachtel, H., Kunow, M., and Löschmann, P.-A. (1992) NBQX (6-nitrosulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazinpropyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats. Neurosci. Lett., 142:179-182.
Weick, B.G., and Walters, J.R. (1987) Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats; D1/D2 coactivation induces potentiated responses. Brain Res., 405:234-246.
Wüllner, U., Kupsch, A., Arnold, G., Renner, P., Scheid, C., Scheid, R., Oertel, W., and Klockgether, T. (1992) The competitive NMDA antagonist CGP40.116 enhances L-Dopa response in MPTP-treated marmosets. Neuropharmacology, 31:713-715.
Young, A.B., Dauth, G.W., Hollingsworth, Z., Penny, J.B., Kaatz, K., and Gilman, S. (1990) Quisqualate-and NMDA-sensitive [3H]glutamate binding in primate brain. J. Neurosci. Res., 27:512-521.
Zadow, B., and Schmidt, W.J. (1994) The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy. Naunyn Schmiedebergs Arch. Pharmacol., 349:61-65.
